Search company, investor...
RenBio company logo

RenBio

renbio.com

Founded Year

2016

Stage

Grant - II | Alive

Total Raised

$41M

Last Raised

$1M | 1 mo ago

About RenBio

RenBio is a preclinical biotechnology company specializing in antibody-based prevention and treatment of diseases. It offers an antibody delivery platform that provides genetic instructions that are delivered by a modified intramuscular injection. Its proprietary nucleic acid therapeutics platform, called MYO (Make Your Own) Technology, is designed to deliver DNA medicines encoding for antibody and protein therapeutics. The company was founded in 2016 and is based in Long Island City, New York.

Headquarters Location

30-02 48th Avenue Suite 600

Long Island City, New York, 10016,

United States

Missing: RenBio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: RenBio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest RenBio News

RenBio Announces the Award of Two Grants to Support Continued Development of Its Novel DNA Therapeutics MYO Technology™ Platform for Infectious Disease Applications

Oct 12, 2022

News provided by Share this article $2.0 Million Grant from the New York State Biodefense Commercialization Fund Approximately $1.0 Million Received as Sub-Awardee of Vanderbilt University Under DARPA's Pandemic Prevention Platform (P3) Program NEW YORK, Oct. 12, 2022 /PRNewswire/ -- RenBio, a privately-held, preclinical biotechnology company leveraging its novel, proprietary MYO (Make Your Own) Technology™ platform to deliver next-generation antibody and protein medicines in the form of DNA therapeutics, today announced that it has received a $2.0 million grant from the Empire State Development's (ESD) New York State Biodefense Commercialization Fund for its proposal, "Rapid Delivery of Monoclonal Antibodies for the Prevention of Future Infectious Disease Outbreaks," and approximately $1.0 million (with an option for an additional $3.6 million), as a sub-awardee of Vanderbilt University Medical Center, under the U.S. Defense Advanced Research Projects Agency (DARPA)'s Pandemic Prevention Platform (P3) program. Created in 2021, the goal of the $40.0 million New York State Biodefense Commercialization Fund is to accelerate the development and commercialization of innovations targeting infectious disease threats while fostering new life science businesses and industry growth within the State. The goal of DARPA's P3 program, founded in 2017, is to support military readiness and global stability through the pursuit of novel methods to dramatically accelerate discovery, integration, preclinical testing, and manufacturing of medical countermeasures against infectious diseases. "The New York State Biodefense Commercialization Fund is an important source of capital for the industry, and we are proud to be one of just eight biotechnology companies selected as an inaugural awardee out of over 100 companies that applied," said Neal N. Padte, Ph.D., Chief Operating Officer and Chief Development Officer of RenBio. "Likewise, we are honored to collaborate with Vanderbilt University Medical Center as part of the DARPA P3 program, leveraging our disruptive MYO Technology to halt the spread of infectious disease outbreaks before they can escalate into pandemics. Rachel A. Liberatore, Ph.D., Chief Scientific Officer of RenBio added, "Frequent dosing regimens, specialized manufacturing, and inconvenient cold-chain requirements are limiting factors for the advancement and use of antibody and protein therapeutics, globally. The work funded by these grants will help us advance our platform validation and IND-enabling studies, and will provide further demonstration of the broad applicability of our MYO Technology platform for the delivery of next-generation medicines in the form of DNA therapeutics." Empire State Development President, CEO and Commissioner, Hope Knight, noted, "New York State's Biodefense Commercialization Fund highlights how we are strategically investing in life science R&D and manufacturing to fuel cutting-edge healthcare solutions that will both save lives and grow jobs. We are proud to support the development of RenBio's MYO Technology DNA therapeutics platform to help pinpoint and prevent serious infectious disease threats, while also growing industry innovation." "The rise of COVID-19 has served as a wake-up call for the need to rapidly respond to infectious disease outbreaks globally," said James E. Crowe, Jr., MD, Ann Scott Professor at Vanderbilt University Medical Center, Director of the Vanderbilt Vaccine Center, and Principal Investigator of the DARPA P3 award. "RenBio's platform has potential to deploy gene-encoded antibodies against future infectious disease outbreaks. We plan to use this approach as part of our DARPA P3 program in order to create an end-to-end pandemic response platform." Additional information regarding the New York State Biodefense Commercialization Fund and DARPA's P3 program can be found by visiting the following links: https://esd.ny.gov/biodefensefund and https://www.darpa.mil/program/pandemic-prevention-platform . About MYO Technology™ The MYO Technology™ platform is built to overcome the challenges inherent in typical antibody and protein therapeutic development, manufacturing, and delivery, by providing patients with a DNA "bioblueprint" that empowers them to produce their own therapeutic antibodies or proteins. The technology utilizes muscle cells (myocytes), converting them into in vivo bioreactors to effectively produce the desired therapeutic within the patient's own body, potentially leading to radically new, longer lasting therapies, negating the need for cold-chain storage and resulting in shorter manufacturing times. About RenBio RenBio is a privately-held, preclinical biotechnology company founded by Columbia University Professors David D. Ho, M.D. and Yaoxing Huang, Ph.D. The Company's novel, next-generation, proprietary nucleic acid therapeutics platform, called MYO (Make Your Own) Technology™, is designed to deliver DNA medicines encoding for antibody and protein therapeutics. The rapid plug-and-play features of the MYO Technology are intended to overcome antibody and protein therapeutic limitations in administration, duration of efficacy, dosing frequency, and cold-chain restrictions, and can rapidly flex to prevent or treat a broad range of diseases. To date, the company has raised $28.0 million in Seed and Series A financing and has received non-dilutive funding from the Defense Advanced Research Projects Agency (DARPA) and the Bill and Melinda Gates Foundation. For more information, visit: https://www.renbio.com/ . Contact:

RenBio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

RenBio Rank

RenBio Frequently Asked Questions (FAQ)

  • When was RenBio founded?

    RenBio was founded in 2016.

  • Where is RenBio's headquarters?

    RenBio's headquarters is located at 30-02 48th Avenue, Long Island City.

  • What is RenBio's latest funding round?

    RenBio's latest funding round is Grant - II.

  • How much did RenBio raise?

    RenBio raised a total of $41M.

  • Who are the investors of RenBio?

    Investors of RenBio include Defense Advanced Research Projects Agency, Empire State Development Corp, Columbia University and Ruentex.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.